Pharvaris

Pharvaris, founded in 2015 and headquartered in Switzerland, is a clinical-stage biopharmaceutical company. The company develops oral B2 receptor antagonists based on novel small-molecule targeting technology for the treatment of HAE and other B2 receptor-mediated indications. Pharvaris brings together management with extensive expertise in drug development and rare diseases, aiming to find new alternatives to injectable therapies for patients with all subtypes of HAE and other B2 receptor-mediated conditions.